{"id":"comparator-voglibose","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Constipation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Voglibose competitively inhibits enzymes (alpha-glucosidase, alpha-amylase) responsible for breaking down disaccharides and complex carbohydrates into monosaccharides. By delaying carbohydrate digestion and absorption, it reduces the postprandial glucose spike in patients with type 2 diabetes. This mechanism helps improve glycemic control without stimulating insulin secretion.","oneSentence":"Voglibose is an alpha-glucosidase inhibitor that slows the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:21.110Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05688332","phase":"PHASE3","title":"Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients","status":"UNKNOWN","sponsor":"University of Zambia","startDate":"2023-08","conditions":"Diabetes Mellitus Type 2 Without Complication","enrollment":118},{"nctId":"NCT00837577","phase":"PHASE3","title":"MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-02-05","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":133},{"nctId":"NCT00411554","phase":"PHASE3","title":"A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":319}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":163,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["voglibose"],"phase":"phase_3","status":"active","brandName":"Comparator: voglibose","genericName":"Comparator: voglibose","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Voglibose is an alpha-glucosidase inhibitor that slows the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose levels. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}